[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351594-105":59,"doc-detail-351594-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","influence-of-gut-microbiota-on-response-to-immune-check-point-inhibitors-in-masld-patients-with-hcc-unraveling-the-connection-review","Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection - Review","","Immune checkpoint inhibitors have become an important option for treating cancers, including advanced hepatocellular carcinoma (HCC). Yet many HCC patients with metabolic dysfunction-associated liver disease (MASLD) show resistance. Evidence links improved ICI outcomes to gut taxa such as Akkermansia, Bifidobacterium, and Lachnoclostridium, whereas expansion of bacteria such as Enterobacteriaceae associates with nonresponse. This review examines how gut dysbiosis shapes ICI responses in MASLD-related HCC and evaluates microbiome modulation strategies, including fecal microbiota transplantation and probiotics, to improve therapeutic efficacy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/influence-of-gut-microbiota-on-response-to-immune-check-point-inhibitors-in-masld-patients-with-hcc-unraveling-the-connection-review/351594/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/influence-of-gut-microbiota-on-response-to-immune-check-point-inhibitors-in-masld-patients-with-hcc-unraveling-the-connection-review/351594.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why do immune checkpoint inhibitors often fail in MASLD-related hepatocellular carcinoma?","Question",{"text":113,"@type":114},"The review explains that MASLD-HCC develops in an immune microenvironment shaped by metabolic inflammation, immunosuppression, and dysbiosis-driven immune dysfunction. This differs from viral-associated HCC where an underlying “viral surveillance” can be more readily reinvigorated by checkpoint blockade.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which gut bacteria are associated with better responses to immune checkpoint inhibitors in HCC?",{"text":118,"@type":114},"The abstract states that certain gut bacteria, including Akkermansia, Bifidobacterium, and Lachnoclostridium, are associated with improved outcomes in ICI-treated HCC patients.",{"name":120,"@type":111,"acceptedAnswer":121},"What microbiome modulation strategies does the review discuss to improve therapeutic outcomes?",{"text":122,"@type":114},"The review focuses on strategies such as fecal microbiota transplantation and probiotics to modulate the gut microbiome and optimize immune checkpoint inhibitor responses.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351594,1790156260,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Cancer Medicine  \nREVIEW  OPEN ACCESS   \nInfluence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection  \nMazen Elsheikh1  | Mohamad Ali Ibrahim1 | Sherry Fares1 | Megha Bhongade1 | Karim Adhem1 |  \nXimena I. Ramirez-Morales1 | Ahmed O. Kaseb2  | Joseph Petrosino3 | Manal M. Hassan4 | Prasun K. Jalal1   \n1Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA | 2Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA | 3Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, Houston, Texas, USA | 4Division of Cancer  \nPrevention and Population Sciences, Department of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA Correspondence: Mazen Elsheikh ([mazen.elsheikh@bcm.edu](mazen.elsheikh@bcm.edu))  \nReceived: 13 August 2025 | Revised: 19 February 2026 | Accepted: 6 March 2026  \nKeywords: dysbiosis | fecal microbial transplantation | immune checkpoint inhibitors  \nABSTRACT  \nImmune checkpoint inhibitors (ICIs) have emerged as a promising treatment for various cancers, including advanced hepatocellular carcinoma (HCC). However, a significant proportion of patients with HCC, particularly those with metabolic dysfunctionassociated liver disease (MASLD), exhibit resistance to ICI therapy. Studies have revealed that the presence of specific gut bacteria, such as Akkermansia, Bifidobacterium, and Lachnoclostridium, is associated with improved outcomes with ICI-treated HCC patients. Conversely, the overgrowth of bacteria like Enterobacteriaceae is linked to resistance to therapy. This review investigates the role of gut microbiota in shaping immune checkpoint inhibitor responses in MASLD-related hepatocellular carcinoma, focusing on how dysbiosis may contribute to ICI resistance and exploring microbiome modulation strategies, such as fecal microbiota transplantation and probiotics, aiming to optimize therapeutic outcomes.  \n1 | Introduction  \nImmune checkpoint inhibitors (ICIs) have emerged as an advanced approach for treating various types of cancer in humans [1, 2] . By unleashing the immune system's natural response, these groundbreaking treatments have expanded the array of choices for dealing with various cancers such as melanoma, breast cancer, liver cancer, and bladder cancer [3] . In advanced hepatocellular carcinoma (HCC), ICIs have proven effective as both first-and second-line treatments [4] . However, while these drugs have revolutionized care for viral-induced HCC, they frequently fail in patients with metabolic dysfunction-associated liver disease (MASLD) HCC [5, 6] .  \nThis apparent paradox largely reflects fundamental differences in the immunologic contexture of these disease states. In viral hepatitis–associated HCC, the immune system can recognize viral antigens presented by infected hepatocytes, eliciting relatively robust virus-specific CD8+ T-cell responses [7] . Although the tumor microenvironment is immunosuppressive, a baseline level of functional, antigen-specific immunity often persists. This underlying “viral surveillance” creates an immune landscape that is more readily reinvigorated by checkpoint blockade [8] .  \nBy contrast, MASLD-HCC develops in a distinct immune milieu shaped by metabolic inflammation, an immunosuppressive  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e71738 1 of 20  \n[https://doi.org/10.1002/cam4.71738](https://doi.org/10.1002/cam4.71738)  \ntumor microenvironment, and dysbiosis-driven immune dysfunction. Unlike viral HCC, the ","cbCaiu842SXbcDh1","https://ap.wps.com/l/cbCaiu842SXbcDh1","pdf",2122724,"English","# Introduction\n## Immune checkpoint inhibitors in cancer and HCC\n## Viral-HCC versus MASLD-HCC immune contexts\n# Dysbiosis and MASLD-HCC\n## Microbial changes across MASLD progression\n## Intestinal barrier disruption and inflammatory signaling\n## Microbial metabolites and hepatocarcinogenesis","[{\"question\":\"Why do immune checkpoint inhibitors often fail in MASLD-related hepatocellular carcinoma?\",\"answer\":\"The review explains that MASLD-HCC develops in an immune microenvironment shaped by metabolic inflammation, immunosuppression, and dysbiosis-driven immune dysfunction. This differs from viral-associated HCC where an underlying “viral surveillance” can be more readily reinvigorated by checkpoint blockade.\"},{\"question\":\"Which gut bacteria are associated with better responses to immune checkpoint inhibitors in HCC?\",\"answer\":\"The abstract states that certain gut bacteria, including Akkermansia, Bifidobacterium, and Lachnoclostridium, are associated with improved outcomes in ICI-treated HCC patients.\"},{\"question\":\"What microbiome modulation strategies does the review discuss to improve therapeutic outcomes?\",\"answer\":\"The review focuses on strategies such as fecal microbiota transplantation and probiotics to modulate the gut microbiome and optimize immune checkpoint inhibitor responses.\"}]","Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection - Review | PDF",1790094868,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0dbf209f1ec92e2351cd5df5919e5b1.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5d46e3e643072272258055df79b9a16.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17a109f1e786cb0c7de5e82ecbcc7c76.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/332c00f3462b31801bb43e52dc78b424.webp",980,1287]